Esbriet (Pirfenidone) Patent Expiration, LOE Window & CMS Spending

Esbriet (Pirfenidone) by Legacy Sezc: FDA Orange Book LOE 2033-08-30, 7 AB generics, $43.6M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorLegacy Sezc
FDA Application & PathwayN022535 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2033-08-30
Orange Book Patents (*PED Extensions)19 patents (0 *PED)
Active AB-Rated Generic Competitors7
2024 CMS Total Public Spend$43.6M
2024 Medicare Part D Spend$42.1M
2024 Medicaid Spend$1.4M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel